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Abstract 22 
Purpose: To investigate the placebo effect of caffeine on pacing strategy and performance 23 
over 1000-m running time-trials using a balanced placebo design. Methods: Eleven well-24 
trained male middle-distance athletes performed seven 1000-m time-trials (one 25 
familiarisation, two baseline and four experimental). Experimental trials consisted of the 26 
administration of four treatments: informed caffeine/received caffeine (CC), informed 27 
caffeine/received placebo (CP), informed placebo/received caffeine (PC), and informed 28 
placebo/received placebo (PP). Treatments were randomized. Split times were recorded at 29 
200-, 400-, 600-, 800- and 1000-m and peak heart rate (HRpeak) and rating of perceived 30 
exertion (RPE) were recorded at the completion of the trial. Results: Relative to baseline, 31 
participants ran faster during CC (d = 0.42) and CP (d = 0.43). These changes were 32 
associated with an increased pace during the first half of the trial. No differences were shown 33 
in pacing or performance between baseline and the PC (d = 0.21) and open administration of 34 
placebo (d = 0.10). No differences were reported between treatments for HRpeak (η2 = 0.084) 35 
and RPE (η2 = 0.009). Conclusions: Our results indicate that the effect of believing to have 36 
ingested caffeine improved performance to the same magnitude as actually receiving 37 
caffeine. These improvements were associated with an increase in pace during the first half of 38 
the time-trial. 39 
Key words: belief, deception, ergogenic aids, nutrition, sport supplements  40 
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Introduction 41 
The placebo effect is a desirable outcome resulting from a person’s belief and/or learned 42 
response to a treatment or situation.1 Although there is considerable evidence for the effect 43 
placebos can have on sports performance,2 empirical evidence within sport and exercise 44 
science has remained largely static in regards to the degree to which placebo effects interact 45 
with the verum components of a treatment. Attempts to quantify the placebo effect in sport 46 
and exercise science often rely exclusively on randomized control trials in which participants’ 47 
belief about the treatment they have been administered is held constant by blinding. Using 48 
this type of design nevertheless does not provide sufficient information about whether there 49 
are any interactions between a treatment and the belief that the treatment will influence 50 
performance.3 Authors in placebo effect research4,5 have therefore advocated the use of the 51 
four-treatment, balanced placebo design,6 which allows an assessment of each possible 52 
combination of what the participant believes they have taken and what they have actually 53 
taken. 54 
To our knowledge, seven studies have used the balanced-placebo design to examine the 55 
placebo effect on sport performance.4,5,7-11 While most studies using this design have reported 56 
significant placebo effects on time-trial performance,5,7,9 few studies have investigated the 57 
potential mechanisms related to its response. Since the mid-1990s, there has been an 58 
exponential increase in the number of studies investigating the placebo effect and the 59 
neurobiological pathways underlying this phenomenon.2 Qualitative data suggest that placebo 60 
effects may be associated with a reduction in pain sensation, arousal regulation and increases 61 
in motivation,12 which may be mediated and moderated by various neurobiological pathways, 62 
such as the endogenous opioid and neurotransmitter pathways.13 However, while there is 63 
mounting evidence of the mechanisms underpinning this phenomenon, it is unclear how 64 
placebo effects affect sport performance during the actual measure itself. It reasonable to 65 
suggest that after ingesting caffeine, for example, athletes may anticipate an offset in fatigue 66 
and alter their exercise behaviour. Thus, athletes’ pacing strategy may depend on their belief 67 
regarding the effect of a substance and their subsequent decisions during performance. 68 
Pacing strategies are set according to an athlete’s expectation of the task they are required to 69 
perform, based on previous experiences that were used to form a performance template.14 70 
Numerous studies have manipulated pacing strategies through deception about timing, the 71 
presence of a competitor and inaccurate feedback.15 Konings and colleagues16 reported that 72 
when riding against a virtual opponent, time to complete 4-km cycling times trials improved 73 
compared to no opponent due to a faster pace at the start of the time-trial. It has been 74 
suggested that this change in pacing behaviour is influenced through neurotransmitters, such 75 
as dopamine, which are affected by motivation, drive and perception of effort.17 Based on 76 
this, if an athlete receives a treatment they believe to be performance enhancing, that athlete 77 
may be more likely to change their pacing strategy, thereby impacting on performance. 78 
However, to the authors’ knowledge, no study has investigated the effects of a placebo 79 
treatment on pacing strategy.  80 
In this study, we used a balanced placebo design to examine the placebo effects of caffeine 81 
on pacing strategy and performance over 1000-m running time-trials. By using a balanced 82 
placebo design, we specifically aimed to: 1) determine the influence both placebo and 83 
caffeine have on performance and 2) analyse participants’ pacing strategies after 84 
administration of deceptive and open treatments of caffeine and placebo. We also aimed to 85 
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establish whether any changes in performance were associated with changes in peak heart 86 
rate and whether this was made possible by participants’ propensity to knowingly exert more 87 
effort.  88 
Method  89 
Participants and statistical power 90 
Eight participants were estimated to provide an a priori statistical power of 0.80. This 91 
estimation was based on a study design using repeated measures ANOVA, an a-value of 0.05 92 
and an explained effect of 1.4 ± 1.6%.18 In case of drop out, fifteen participants were initially 93 
recruited. Four withdrew (two due to injury and two because of a conflicting timetable), 94 
leaving eleven well-trained male middle-distance athletes (mean ± SD: age = 25.2 ± 5.6 yrs; 95 
height = 176.3 ± 8.1 cm; body mass = 66.8 ± 6.1 kg; daily caffeine consumption; 269 ± 43 96 
mg·d-1). Eligibility criteria stipulated that participants must be nationally ranked in the United 97 
Kingdom for 800-, 1500-, 3000- or 5000-m, aged between 18 and 35 and have trained 98 
minimally five days per week for at least 3 months prior to the start of the study. Only light-99 
moderate caffeine (200-350 mg·day-1) users were included in the study to control for 100 
individual differences and familiarity of the effects of caffeine.19 The study was anticipated to 101 
last approximately four weeks. For this reason, only males were recruited to avoid 102 
confounding performance variation in the mid-luteal phase of the menstrual cycle.20 103 
Institutional ethics approval was granted, in agreement with the Declaration of Helsinki. 104 
Participants were informed that participation was voluntary and they had the right to 105 
withdraw at any time during the course of the study. Participants provided written informed 106 
consent after reading the study information sheet. 107 
Design 108 
We used a quasi-randomised, repeated measures, balanced placebo design to determine the 109 
effects of caffeine and placebo on 1000-m running time-trial performance. Participants 110 
performed seven trials: familiarisation, two baseline and four as part of the balanced placebo 111 
design. The four balanced placebo design trials were as follows: 112 
1. Informed caffeine and given caffeine (CC) – participants were informed they received 113 
caffeine and did 114 
2. Informed caffeine and given placebo (CP) – participants were informed they received 115 
caffeine but received placebo 116 
3. Informed placebo and given caffeine (PC) – participants were informed they received 117 
placebo but received caffeine 118 
4. Informed placebo and given placebo (PP) – participants were informed they received 119 
placebo and did 120 
The balanced-placebo 1000-m trials were randomised using a computer generated 121 
programme (www.randomization.com) and participants were deceived about the treatment 122 
they received in CP and PC. Particiapts ran 1000-m and split times were recorded at 200-, 123 
400-, 600-, 800- and 1000-m. Peak heart rate (HRpeak) and ratings of perceived exertion 124 
(RPE) were recorded immediately after the trial.  125 
Performance measure and equipment 126 
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All trials were run on a 400-m, tartan track, in accordance with the International Association 127 
of Athletics Federation’s standards (polymer synthetic tartan track, with a depth of three 128 
centimetres). Participants ran two and a half laps (1000-m) around the track as fast as 129 
possible, with no assistance (e.g. pacemakers or external feedback). Times and splits were 130 
measured using an automated, single-beam photocell, light gate system (Smartspeed ProTM, 131 
Fusion Sport Inc., Australia) and were mounted in lane 1 of the 200- and 400-m start/finish 132 
line. Single-beam light gate systems are the most common method for measuring running 133 
performance and have shown to have good reliability.21 Weather measurements for wind 134 
speed (m/s), temperature (°C), relative humidity (%) and wind chill (°C) were recorded using 135 
the Pasco weather sensor (PS-2174, Pasco, Roseville CA, USA) attached to the Xplorer GLX 136 
graphing data-logger (PS-2002, Pasco, Roseville CA, USA). Minimal differences were 137 
reported for all time-trials (wind speed = 0.5 ± 0.2m/s; temperature = 18.5 ± 1.9°C; relative 138 
humidity = 53.5 ± 0.9%).Caffeine and placebo treatments 139 
Based on previous research in the deceptive administration of caffeine,4 in the CC and CP 140 
treatments, participants ingested 200-mL of chilled saline with 3.0 mg·kg-1 of anhydrous 141 
caffeine (Myprotein; Norwich, England). The dosage of 3.0 mg·kg-1 caffeine was chosen as it 142 
has been suggested to be optimal for improving performance lasting ~3-minutes.22 Given that 143 
peak plasma caffeine typically occurs 45-minutes post-ingestion,23 participants were asked to 144 
consume the treatments 1-hour prior to the start of the time-trial. In the CP and PP treatments, 145 
participants consumed 200-mL of chilled saline only. In placebo effect research, the validity 146 
of the balanced-placebo design relies on the credibility of the deception in the CP and PC 147 
treatments. Extensive pilot testing was therefore conducted to ensure that no taste or 148 
palpability differences could be identified between placebo and caffeine treatments.  149 
Belief manipulation 150 
Before any data collection, participants attended a short presentation on the benefits of 151 
caffeine on middle-distance running performance delivered by the first author. Participants 152 
were provided with literature reviewing the findings of published research on caffeine and 153 
middle-distance running and were informed that caffeine was previously a banned 154 
performance enhancing substance. To further augment the belief that caffeine is performance 155 
enhancing, and in line with current recommendations for reporting fine details of participant 156 
contact and communication,2 anecdotal evidence relating to the first authors’ experience in 157 
the use of caffeine was explained. At the time of data collection, the first author competed as 158 
an international level athlete against notable Olympians and participants were informed that 159 
caffeine acted as potent ergogenic aid during competition. The efficacy of this manipulation 160 
of beliefs was supported by data collected in post-study interviews.   161 
Procedure 162 
Participants performed seven 1000-m running time-trials. All trials were performed on 163 
Monday and Friday evening at the same location. The time between trials allowed an 164 
adequate wash out period for caffeine supplementation24 and is sufficient for middle-distance 165 
trained athletes to fully recover.25  166 
For all trials, participants were instructed to arrive in 'race-shape' condition. High intensity 167 
exercise 48 hours preceding the trials was not permitted, as well as the consumption of 168 
alcohol or sport supplements. Participants were asked to adhere to their regular pre-race diet, 169 
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rest and warm-up routines. Participants began all trials at the same time of day to minimise 170 
circadian variation in performance26 and each trial was started by a green LED, which would 171 
flash up on the photocell. To limit the potential for participants to employ pacing strategies 172 
based on knowledge of previous trials and performance during trials, they did not to wear a 173 
watch and were given no encouragement. No information about split times was given and the 174 
results of the trials were given after all data had been collected. HRpeak was recorded using a 175 
Polar stopwatch (Heart Monitors, Polar Ltd, Finland) and RPE from 0 (nothing at all) to 10 176 
(maximal) was measured using the Borg Category Ratio27 immediately after participants 177 
completed the trial.    178 
For familiarisation trials, participants were informed: “Today you are performing a 179 
familiarisation trial” and for baseline trials 1 and 2, participants were informed “Today you 180 
are performing a baseline trial”. For balanced placebo design trials, participants were further 181 
reminded about which treatment they had received. For CC and CP treatments, participants 182 
were informed: “Today you will be performing the trial with caffeine” and for PC and PP 183 
treatments, participants were told: “Today you will be performing the trial with no caffeine.” 184 
Upon completion of all data collection, participants were debriefed about the true nature of 185 
the study.  186 
Data analysis 187 
Times to complete the 1000-m time-trials for baseline 1 and baseline 2 and each split (200-, 188 
400-, 600-, 800- and 1000-m) were inputted into an online reliability spreadsheet.28 Data 189 
were log transformed to reduce nonuniform errors and the intraclass correlation (ICC) and 190 
Pearson correlation (r) provided estimates of reliability. The precision of ICC was interpreted 191 
as extremely high (0.99); very high (0.90), high (0.75) moderate (0.50) and low (0.20).28 r 192 
was interpreted as trivial (<0.1), small (0.3), moderate (0.5), large (0.5), very large (0.7), 193 
nearly perfect (0.9) and perfect (1.0). In addition, paired samples t-tests were conducted to 194 
determine any systematic difference in performance between baseline 1 and baseline 2.  195 
Data were entered into SPSS version 24.0 (IBM, Armonk, NY) and tested for homogeneity of 196 
variance, normal distribution and anomalies. Repeated measures ANOVA identified 197 
differences in time to complete 1000-m time-trials between each treatment (i.e. baseline, CC, 198 
CP, PC and PP) and split (i.e. 200-, 400-, 600-, 800- and 1000-m). Differences in HRpeak, 199 
RPE and mean time to complete the 1000-m trials between each treatment were also 200 
established using repeated measures ANOVA. Greenhouse-Geisser epsilon was reported 201 
when sphericity was violated and post-hoc LSD tests were used. Cohen’s d was calculated to 202 
determine the effect size (d) of the mean differences. Differences between 0.2 and <0.5 were 203 
interpreted as a small effect, between 0.5 and <0.8 as moderate, and >0.8 as large.29 Data are 204 
presented as mean ± standard error of the mean with statistical significance set at p<0.05  205 
Results 206 
Times were similar between baseline 1 and baseline 2 at 200- (mean differences = -0.48 ± 207 
0.34 s, P = .290, r = 0.897, ICC = 0.90), 400- (0.04 ± 0.40 s, p = 0.936, r = 0.776, ICC = 208 
0.77), 600- (-0.56 ± 0.30 s, p = 0.217, r = 0.885, ICC = 0.85), 800- (-0.13 ± 0.53 s, p = 0.149, 209 
r = 0.584, ICC = 0.61) and 1000-m (0.60 ± 0.61 s, p = 0.189, r = 0.614, ICC = 0.67). The 210 
average of these two time-trials was thus used to measure baseline. Mean times to complete 211 
1000-m trials in all treatments are shown in table 1.  212 
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 213 
Main analyses 214 
 215 
Repeated measures ANOVA (treatment × split) reported differences between treatment (F(4, 216 
160) = 6.162, p = 0.006; η2 = 0.381) and split (F(4, 160) = 9.288, p < 0.001; η2= 0.482). No 217 
difference in time was shown for treatment × split (F(4, 160) = 1.055, p = 0.266; η2= 0.108). 218 
Differences in time between treatments 219 
Compared to baseline, participants ran faster in CC (mean differences = 0.64 ± 0.11 s, p 220 
<0.001, d = 0.42) and CP (0.66 ± 0.18 s, p = 0.004, d = 0.43) treatments. Compared to PP, 221 
participants ran faster in CC (0.80 ± 0.18 s, p = 0.001, d = 0.47) and CP (0.83 ± 0.21 s, p = 222 
0.002, d = 0.48) treatments. All differences between mean times to complete the trials and 223 
treatments are shown in figure 1.  224 
Differences in treatment between splits 225 
At the 200-m split and compared to PP, participants ran faster in CC (mean differences = 226 
0.94 ± 0.29 s, p = 0.009, d = 0.42) and CP (1.21 ± 0.38 s, p = 0.010, d = 0.57). At the 400-m 227 
split, participants ran faster in CC compared to baseline (-0.87 ± 0.25, p = 0.006, d = 0.55), 228 
PC (-0.91 ± 0.28 s, p = 0.009, d = 0.54) and PP (-1.69 ± 0.28 s, p = 0.001, d = 0.84). 229 
Similarly, participants ran faster at 400-m in CP compared to baseline (-0.68 ± 0.27 s, p = 230 
0.031, d = 0.41), PC (-0.72 ± 0.31 s, p = 0.044, d = 0.41) and PP (-1.40 ± 0.28 s, p = 0.001, d 231 
= 0.72). At the 600-m split, participants ran faster in CP compared to baseline (-0.94 ± 0.27 s, 232 
p = 0.005, d = 0.64) and PP (-0.81 ± 0.33 s, p = 0.043, d = 0.47). Participants also ran faster 233 
at 600-m in PC compared to baseline (-1.01 ± 0.31 s, p = 0.008, d = 0.60), CC (-0.61 ± 0.23 s, 234 
p = 0.024, d = 0.36) and PP (-0.88 ± 0.33 s, p = 0.023, d = 0.46). No differences were shown 235 
between any treatments at the 800-m split (p > 0.05), but participants ran faster at 1000-m in 236 
CC compared to baseline (-1.08 ± 0.43 s, p = 0.030, d = 0.52) and PP (-0.98 ± 0.40 s, p = 237 
0.035, d = 0.45). All differences between each treatment and split are shown in figure 2.  238 
Differences in peak heart rate and RPE between treatments 239 
Repeated measures ANOVA revealed no differences between treatments for HRpeak (F(4, 40) = 240 
1.198, p = 0.327, η2 = 0.084) and RPE (F(4, 40) = 0.892, p = 0.641, η2 = 0.009). Across all 241 
treatments, mean HRpeak and RPE average scores ranged from 180 to 184 bpm (183.5 ± 2.3 242 
bpm) and 9 to 10 (9.6 ± 0.4), respectively.  243 
Discussion 244 
We used a balanced placebo design to investigate the effect of a placebo and caffeine on 245 
pacing strategy during 1000-m running time-trials. Collectively, our results indicate that the 246 
belief of receipt of caffeine improved performance, which was associated with a significant 247 
increase in speed during the first 400-m of the time-trial. In contrast, the hidden and open 248 
administration of caffeine and placebo, respectively, did not improve performance compared 249 
to baseline. Participants ran faster between 400- and 600-m during the hidden administration 250 
of caffeine, but time to complete the trial overall was similar to baseline.  251 
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In our study, the effect of believing to have ingested caffeine improved performance to the 252 
same magnitude as actually receiving caffeine. These findings complement previous findings 253 
in this area, in which participants were able to significantly improve their performance after 254 
being falsely informed they had received caffeine.30,31 However, in addition to previous 255 
studies investigating the placebo effect of caffeine,4,30-32 we also examined participants’ 256 
pacing strategy during the trial, in order to establish if a change in pacing might help explain 257 
the performance improvements. Given that we informed participants that they had received 258 
caffeine in the CC and CP treatments, this information appears to have influenced their belief 259 
of how fast they could perform, influencing the goal-directed process of decision-making 260 
regarding how to distribute the available energy resources.33 Results indicated that 261 
participants were significantly faster at 400-m than baseline and also faster at 200- and 400-m 262 
than when they were given a placebo and informed it was a placebo. This highlights that the 263 
belief of receipt of caffeine, influences the pacing strategy at the start of a 1000-m running 264 
time-trial, impacting on performance.  265 
While both belief and actual receipt of caffeine improved performance at the start of the time-266 
trial, only the actual receipt of caffeine improved performance in the latter stages. At 1000-m, 267 
participants ran significantly faster than baseline during the open administration of caffeine. 268 
This suggests that caffeine may offset fatigue during the final stages of a 1000-m time-trial. It 269 
has been reported that caffeine directly affects neuromuscular output,34 which increases 270 
muscular endurance and subsequently offsets fatigue.35 However, no improvements in 271 
performance at 1000-m were shown during the hidden administration of caffeine. Therefore, 272 
the belief of receipt of caffeine was primarily responsible for the ergogenic effect of caffeine. 273 
These results are similar to Atlas and colleagues, 36 who reported that the benefits of an 274 
opioid drug were augmented after open administration compared to hidden and to a placebo 275 
described as the drug. In the same study, follow up fMRI data revealed that drug and placebo 276 
effects activate different neurobiological pathways, suggesting that the benefits from the drug 277 
and placebo are additive. From the results reported in the present study, it could be suggested 278 
that caffeine and placebo use different neurobiological pathways that affect performance. 279 
Thus, when caffeine is administered openly, the verum and placebo components of caffeine 280 
may combine to provide a greater improvement in performance. However, while these data 281 
show additive effects for caffeine in the latter stages of the trial, it does not exclude the 282 
possibility that other treatments may show interactive effects (i.e. use the same mechanisms). 283 
A paucity of evidence in sport and exercise science is available in this area and future 284 
research needs to design studies that examines the additive or interactive effects of treatments 285 
and placebos.  286 
Table 1 shows large variability between each treatment, which indicates that some 287 
participants may be more likely to respond to a placebo than others. It is recognised that a 288 
participant responding to a placebo can vary from study to study1,2 and even those who do 289 
respond, may not do so consistently.37 Researchers often focus on single-factor casual 290 
mechanisms such as expectation theory4,31 or classical conditioning.38,39 However, placebo 291 
effects are a manifestation of several factors, such as the context in which the treatment is 292 
administered, the person administering it, and the psychology of the athlete (e.g. personality, 293 
beliefs, and intentions). Beedie et al. 37 suggest that variability of the placebo effect can be a 294 
function of 1) an athlete’s response to the verum component of a treatment (e.g. caffeine); 2) 295 
an athletes response to the placebo component only; and 3) an athletes response to both the 296 
verum and placebo component. To increase knowledge and understanding of the placebo 297 
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effect, research is needed that helps identify the mechanisms underlying the variation in 298 
placebo responsiveness.  299 
Similar to previous research,4,31,40 no differences in peak heart rate or perceived exertion was 300 
found between treatments. Given that the aim of a pacing strategy is to ensure physiological 301 
limits are not surpassed while performing at an optimal level,15 a limitation of this study was 302 
that the growth curve of heart rate and perceived exertion during each trial was not measured. 303 
Future research should measure the differences in slopes of heart rate and RPE at each split to 304 
provide a better insight into the variability in intraindividual patterns of change over time 305 
between treatments.  306 
 307 
Conclusion 308 
In conclusion, this is the first study to show that the belief of receipt of caffeine improves 309 
1000-m running time-trial performance on competitive level athletes. That is, believing to 310 
have ingested caffeine, improved performance to the same magnitude as actually receiving 311 
caffeine. These improvements were associated with an increase in speed during the first-part 312 
of the time-trial. While slight changes in pacing strategy were demonstrated during the mid-313 
part of the time-trial with the hidden ingestion of caffeine, overall no changes compared to 314 
baseline were shown. Therefore, for practitioners aiming to maximise the benefits of caffeine 315 
on an athlete’s performance, they should couple the administration of caffeine with a positive 316 
belief of its effectiveness to increase the likelihood of that athlete improving performance.  317 
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Figure captions 417 
Figure 1. Mean split time between each treatment. Note: Data are means ± 95% CI. * = p < 418 
0.01 vs. CC and CP. ** = p < 0.01 vs. CC and CP 419 
Figure 2. Differences in times between treatment and splits. Note: *PP vs. CC and CP (p < 420 
0.05). **CC and CP vs. baseline, PC and PP (p < 0.05). #PC vs. baseline, CC and PP(p < 421 
0.05) and CP vs. baseline and PP (p < 0.05). †CC vs. baseline and PP (p < 0.05) 422 
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Tables 423 
Table 1. Mean times (s) to complete 1000-m time-trials in each treatment 
Participant Baseline CC CP PC PP 
1 166.9 164.3 165.4 172.1 165.1 
2 187.3 182.9 180.9 187.1 193.1 
3 179.4 174.9 175.4 174.7 178.2 
4 176.4 171.1 170.5 173.7 175.3 
5 168.4 164.1 160.3 163.0 164.8 
6 180.4 178.4 178.7 177.8 184.5 
7 169.3 164.6 165.9 165.9 169.8 
8 166.3 162.5 163.7 164.3 168.1 
9 183.3 180.4 179.2 182.4 181.6 
10 175.2 173.3 173.6 173.9 179.1 
11 181.8 182.8 184.4 182.4 183.9 
Mean ± SEM 175.9 ± 0.55 172.7 ± 0.60 172.6 ± 0.60 174.3 ± 0.59 176.7 ± 0.68 
Note: CC = Told caffeine/given caffeine; CP = Told caffeine/given placebo; PC = Told placebo/given caffeine; PP = Told placebo/given 
placebo 
